{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T08:50:34Z","timestamp":1783759834586,"version":"3.55.0"},"reference-count":34,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T00:00:00Z","timestamp":1587513600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Teijin Pharma Limited, Japan"}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"DOI":"10.1371\/journal.pmed.1003095","type":"journal-article","created":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T17:25:46Z","timestamp":1587576346000},"page":"e1003095","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":80,"title":["Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3352-7661","authenticated-orcid":true,"given":"Atsushi","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0183-2541","authenticated-orcid":true,"given":"Hiroki","family":"Teragawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobukazu","family":"Ishizaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1228-1201","authenticated-orcid":true,"given":"Yumiko","family":"Kanzaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Tomiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Sata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Sezai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1841-6728","authenticated-orcid":true,"given":"Kazuo","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8304-4516","authenticated-orcid":true,"given":"Toru","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8260-833X","authenticated-orcid":true,"given":"Shigeru","family":"Toyoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2535-5396","authenticated-orcid":true,"given":"Ryoichi","family":"Ishibashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8251-4480","authenticated-orcid":true,"given":"Kazuomi","family":"Kario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3794-899X","authenticated-orcid":true,"given":"Tomoko","family":"Ishizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0456-0841","authenticated-orcid":true,"given":"Shinichiro","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Maemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihito","family":"Higashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3741-5560","authenticated-orcid":true,"given":"Hirotsugu","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Ohishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Yokote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2723-6243","authenticated-orcid":true,"given":"Toyoaki","family":"Murohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4335-5795","authenticated-orcid":true,"given":"Jun-ichi","family":"Oyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2534-0939","authenticated-orcid":true,"given":"Koichi","family":"Node","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the PRIZE study investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,4,22]]},"reference":[{"key":"pmed.1003095.ref001","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1681\/ASN.2005121331","article-title":"Serum uric acid: a risk factor and a target for treatment?","volume":"17","author":"DI Feig","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"pmed.1003095.ref002","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMra0800885","article-title":"Uric acid and cardiovascular risk","volume":"359","author":"DI Feig","year":"2008","journal-title":"N Engl J Med"},{"key":"pmed.1003095.ref003","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1161\/HYPERTENSIONAHA.116.08998","article-title":"Asymptomatic hyperuricemia without comorbidities predicts cardiometabolic diseases: five-year Japanese cohort study","volume":"69","author":"M Kuwabara","year":"2017","journal-title":"Hypertension"},{"key":"pmed.1003095.ref004","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/nrrheum.2014.124","article-title":"Improving cardiovascular and renal outcomes in gout: what should we target?","volume":"10","author":"P Richette","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"pmed.1003095.ref005","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jjcc.2012.01.013","article-title":"Relationships among hyperuricemia, endothelial dysfunction and cardiovascular disease: molecular mechanisms and clinical implications","volume":"59","author":"P Puddu","year":"2012","journal-title":"J Cardiol"},{"key":"pmed.1003095.ref006","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.atherosclerosis.2014.10.006","article-title":"Xanthine oxidoreductase in atherosclerosis pathogenesis: not only oxidative stress","volume":"237","author":"MG Battelli","year":"2014","journal-title":"Atherosclerosis"},{"key":"pmed.1003095.ref007","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1038\/srep04554","article-title":"Xanthine oxidase inhibition by febuxostat attenuates experimental atherosclerosis in mice","volume":"4","author":"J Nomura","year":"2014","journal-title":"Sci Rep"},{"key":"pmed.1003095.ref008","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.freeradbiomed.2006.03.026","article-title":"Xanthine oxidase inhibitor tungsten prevents the development of atherosclerosis in ApoE knockout mice fed a Western-type diet","volume":"41","author":"K Schroder","year":"2006","journal-title":"Free Radic Biol Med"},{"key":"pmed.1003095.ref009","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"MA Becker","year":"2005","journal-title":"N Engl J Med"},{"key":"pmed.1003095.ref010","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.freeradbiomed.2011.04.004","article-title":"Febuxostat inhibition of endothelial-bound XO: implications for targeting vascular ROS production","volume":"51","author":"UZ Malik","year":"2011","journal-title":"Free Radic Biol Med"},{"key":"pmed.1003095.ref011","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1253\/circj.CJ-13-0082","article-title":"Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients (NU-FLASH Trial)","volume":"77","author":"A Sezai","year":"2013","journal-title":"Circ J"},{"key":"pmed.1003095.ref012","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout","volume":"378","author":"WB White","year":"2018","journal-title":"N Engl J Med"},{"key":"pmed.1003095.ref013","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12872-018-0757-9","article-title":"Xanthine oxidase inhibitors for prevention of cardiovascular events: a systematic review and meta-analysis of randomized controlled trials","volume":"18","author":"M Bredemeier","year":"2018","journal-title":"BMC Cardiovasc Disord"},{"key":"pmed.1003095.ref014","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12933-016-0409-2","article-title":"Rationale and design of a multicenter randomized study for evaluating vascular function under uric acid control using the xanthine oxidase inhibitor, febuxostat: the PRIZE study","volume":"15","author":"J Oyama","year":"2016","journal-title":"Cardiovasc Diabetol"},{"key":"pmed.1003095.ref015","doi-asserted-by":"crossref","first-page":"846","DOI":"10.5551\/jat.GL2017","article-title":"Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017","volume":"25","author":"M Kinoshita","year":"2018","journal-title":"J Atheroscler Thromb"},{"key":"pmed.1003095.ref016","doi-asserted-by":"crossref","first-page":"e1002051","DOI":"10.1371\/journal.pmed.1002051","article-title":"The effect of sitagliptin on carotid artery atherosclerosis in type 2 diabetes: the PROLOGUE randomized controlled trial","volume":"13","author":"J Oyama","year":"2016","journal-title":"PLoS Med"},{"key":"pmed.1003095.ref017","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.echo.2007.11.011","article-title":"Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine","volume":"21","author":"JH Stein","year":"2008","journal-title":"J Am Soc Echocardiogr"},{"key":"pmed.1003095.ref018","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1475-2840-9-40","article-title":"Carotid intima-media thickness in individuals with and without type 2 diabetes: a reproducibility study","volume":"9","author":"L Lundby-Christensen","year":"2010","journal-title":"Cardiovasc Diabetol"},{"key":"pmed.1003095.ref019","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.atherosclerosis.2011.01.048","article-title":"Prognostic impact of plaque echolucency in combination with inflammatory biomarkers on cardiovascular outcomes of coronary artery disease patients receiving optimal medical therapy","volume":"216","author":"T Ishizu","year":"2011","journal-title":"Atherosclerosis"},{"key":"pmed.1003095.ref020","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ijcard.2017.11.022","article-title":"Longitudinal association among endothelial function, arterial stiffness and subclinical organ damage in hypertension","volume":"253","author":"H Tomiyama","year":"2018","journal-title":"Int J Cardiol"},{"key":"pmed.1003095.ref021","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.2169\/internalmedicine.54.4310","article-title":"The effects of allopurinol on the carotid intima-media thickness in patients with type 2 diabetes and asymptomatic hyperuricemia: a three-year randomized parallel-controlled study","volume":"54","author":"P Liu","year":"2015","journal-title":"Intern Med"},{"key":"pmed.1003095.ref022","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1136\/heartjnl-2014-305683","article-title":"Allopurinol reduces brachial and central blood pressure, and carotid intima-media thickness progression after ischaemic stroke and transient ischaemic attack: a randomised controlled trial","volume":"100","author":"P Higgins","year":"2014","journal-title":"Heart"},{"key":"pmed.1003095.ref023","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1161\/HYPERTENSIONAHA.115.06344","article-title":"Allopurinol and cardiovascular outcomes in adults with hypertension","volume":"67","author":"RL MacIsaac","year":"2016","journal-title":"Hypertension"},{"key":"pmed.1003095.ref024","doi-asserted-by":"crossref","first-page":"653.e7","DOI":"10.1016\/j.amjmed.2015.01.013","article-title":"Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: a cohort study","volume":"128","author":"SC Kim","year":"2015","journal-title":"Am J Med"},{"key":"pmed.1003095.ref025","doi-asserted-by":"crossref","first-page":"1076189","DOI":"10.1155\/2019\/1076189","article-title":"Febuxostat and cardiovascular events: a systematic review and meta-analysis","volume":"2019","author":"JA Cuenca","year":"2019","journal-title":"Int J Rheumatol"},{"key":"pmed.1003095.ref026","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1161\/CIRCULATIONAHA.118.033992","article-title":"Assessment of cardiovascular risk in older patients with gout initiating febuxostat versus allopurinol","volume":"138","author":"M Zhang","year":"2018","journal-title":"Circulation"},{"key":"pmed.1003095.ref027","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1080\/15257770.2011.596496","article-title":"Japanese Society of Gout and Nucleic Acid Metabolism. Japanese guideline for the management of hyperuricemia and gout: second edition","volume":"30","author":"H Yamanaka","year":"2011","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"pmed.1003095.ref028","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"P Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"pmed.1003095.ref029","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"D Khanna","year":"2012","journal-title":"Arthritis Care Res"},{"key":"pmed.1003095.ref030","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1159\/000489145","article-title":"Urate-lowering agents in asymptomatic hyperuricemia: role of urine sediment analysis and musculoskeletal ultrasound","volume":"43","author":"D Viggiano","year":"2018","journal-title":"Kidney Blood Press Res"},{"key":"pmed.1003095.ref031","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1093\/eurheartj\/ehz119","article-title":"Febuxostat for cerebral and caRdiorenovascular events prEvEntion stuDy","volume":"40","author":"S Kojima","year":"2019","journal-title":"Eur Heart J"},{"key":"pmed.1003095.ref032","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1053\/j.ajkd.2018.06.028","article-title":"Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial","volume":"72","author":"K Kimura","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"pmed.1003095.ref033","doi-asserted-by":"crossref","first-page":"e007720","DOI":"10.1161\/JAHA.117.007720","article-title":"Impact of intima-media thickness progression in the common carotid arteries on the risk of incident cardiovascular disease in the suita study","volume":"7","author":"Y Kokubo","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"pmed.1003095.ref034","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1161\/HYPERTENSIONAHA.107.093260","article-title":"Hypertension and hypercholesterolemia differentially affect the function and structure of pig carotidartery","volume":"50","author":"D Versari","year":"2007","journal-title":"Hypertension"}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1003095","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T17:26:05Z","timestamp":1587576365000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1003095"}},"subtitle":[],"editor":[{"given":"Claudio","family":"Borghi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,4,22]]},"references-count":34,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,4,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1003095","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,22]]}}}